The company's name, Biel Glasses, comes from Biel, a child born with a condition that causes low vision. Low vision is a visual impairment seven times more common than total blindness; it does not lead to complete blindness but makes daily tasks difficult to perform. It cannot be corrected with conventional glasses or surgery. Its most disabling effect is mobility limitation due to the risk of falls, collisions, and disorientation, which lead to dependency and social isolation. The most severe mobility problems occur when there is a loss of peripheral vision, as in glaucoma and retinitis, affecting more than 70 million people worldwide. The estimated impact exceeds €15,000 per person per year in developed countries, totaling over €100 billion annually in Europe alone.

Although the company was founded because of a child, most people with low vision are older, as the majority of conditions causing it are progressive.

57% of patients are willing to pay up to €5,000 for a solution to these problems, representing a total addressable market (TAM) of over €9 billion in Europe alone. This market has significant growth potential as we introduce our product to the U.S. and the rest of the world.

Until now, the only solutions available have been guide dogs, canes, and navigation apps like Google Maps. White canes are very limited and do not provide real autonomy. Guide dogs are a much better option, but they cost over €30,000 and can take years to obtain. Navigation apps do not detect obstacles, are not very accessible, and are too imprecise for people with low vision.

Our solution, BIEL SMARTGAZE, consists of smart glasses that use AI and mixed reality (MR) to adapt reality to the patient’s remaining vision, allowing them to move safely. Additionally, they include highly useful visual enhancements such as zoom vision, contrast improvement, and adaptive lighting adjustments, providing complete autonomy.

What patients are saying:

Ivanna Caraccio: "With Biel Glasses, I can be more independent and go to places I couldn't before." – Pilot Patient, Barcelona 2024

Lluís Fortuny: "I feel safer with these glasses, especially for objects that appear blurry. The glasses help me see objects more clearly and make me aware that I need to pay attention to them."

Throughout its development, we have tested BIEL SMARTGAZE in various mobility situations within our laboratory, built with the support of EIT Health at the School of Optometry of Terrassa (Polytechnic University of Catalonia). The tests have shown an 80% improvement in patient mobility. BIEL SMARTGAZE is certified at the European level as a Class 1 medical device (MDR).

We have conducted several pilot projects in four cities, the most significant one in Barcelona, where we tested the glasses with over 30 patients in collaboration with the Barcelona City Council, the Government of Catalonia, UPC, and Mobile World Capital. Additionally, we maintain ongoing collaboration with leading institutions and associations related to low vision.

So far, we have secured over €4 million in R&D funding, which has enabled the development of our Biel Smartgaze device. The goal of this crowdfunding campaign is to obtain the necessary private funding to launch its commercialization. In 2025, we will begin commercialization in Europe, with plans to expand into the U.S. and Asia in 2026. We already have pre-distribution agreements in Spain, Denmark, the Netherlands, the U.S., and Canada, including with Essilor Luxottica, the global leader in optics.

At Biel Glasses, we are committed to continuous innovation. We are already developing the next version of our device, which will feature an improved design, reducing its size and weight, while incorporating new functions such as safe and accessible navigation and street-crossing assistance.

ATTENTION: The investment round in Biel Glasses is structured through an Investment Company. There is a circumstance we must highlight: if, at the time capital gains are generated, the Investment Company’s stake in Biel Glasses has been reduced below 5%, these capital gains will be subject to double taxation due to the non-exemption of corporate tax. We will implement mechanisms to try to avoid this, but you should be aware of this circumstance.